The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

QX004N, an interleukin-23 inhibitor, showed safety and efficacy in the treatment of moderate to severe plaque psoriasis, according to a study. QX004N, an IL-23 inhibitor, showed safety and ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque ... whole body psoriasis, who might respond differently to the treatment.

The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

You can apply sunscreen to psoriasis plaques to prevent sunburn, but, if the plaques from psoriasis are inflamed or cracked ...